{"id":"NCT04986202","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2021-06-30","primaryCompletion":"2024-03-27","completion":"2024-03-27","firstPosted":"2021-08-02","resultsPosted":"2025-08-27","lastUpdate":"2025-08-27"},"enrollment":711,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Failure With Preserved Ejection Fraction"],"interventions":[{"type":"DRUG","name":"AZD4831","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Part A 2.5 mg","type":"EXPERIMENTAL"},{"label":"Part A 5 mg","type":"EXPERIMENTAL"},{"label":"Part A Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Part B Dose based on Part A","type":"EXPERIMENTAL"},{"label":"Part B Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fraction \\> 40%. The study will consist of 2 separate parts, Part A and Part B, approximately 660 participants will be randomised in Part A, 820 in Part B.","primaryOutcome":{"measure":"Kansas City Cardiomyopathy Questionnaire -Total Symptom Score","timeFrame":"Baseline - 16 weeks","effectByArm":[{"arm":"AZD4831 2.5 mg","deltaMin":10.7,"sd":null},{"arm":"AZD4831 5 mg","deltaMin":9.81,"sd":null},{"arm":"Placebo","deltaMin":11.62,"sd":null}],"pValues":[{"comp":"OG000","p":"0.537"},{"comp":"OG001","p":"0.221"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":171,"countries":["United States","Australia","Belgium","Brazil","Bulgaria","Canada","Czechia","Denmark","France","Hungary","Japan","Netherlands","Poland","Russia","Slovakia","Sweden","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["37470101"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6580C00010&amp;attachmentIdentifier=d0341baa-e973-48d0-95d4-91c806b29fca&amp;fileName=D6580C00010_Redacted_CSP.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6580C00010&amp;attachmentIdentifier=ac832783-a7d5-46b3-8823-8d5a77d1fa45&amp;fileName=D6580C00010-Redacted_CSR_synopsis.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6580C00010&amp;attachmentIdentifier=c7691e40-e2a4-4c14-826f-c6b7fe018451&amp;fileName=D6580C00010_Redacted_SAP.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":60,"n":234},"commonTop":["Covid-19","Dizziness","Nasopharyngitis","Cardiac failure"]}}